(Q40679809)

22 September 2017

title

The cost utility analysis of riluzole for the treatment of amyotrophic lateral sclerosis in the UK. (English)

1 reference

amyotrophic lateral sclerosis

22 September 2017

main subject

0 references

author name string

M Tavakoli

series ordinal

1

1 reference

22 September 2017

M Malek

series ordinal

2

1 reference

22 September 2017

publication date

1 October 2001

1 reference

Journal of the Neurological Sciences

22 September 2017

published in

1 reference

22 September 2017

volume

191

1 reference

22 September 2017

issue

1-2

1 reference

22 September 2017

page(s)

95-102

1 reference

An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole

22 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900618-9

Palliative care in amyotrophic lateral sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900618-9

The Scottish Motor Neuron Disease Register: a prospective study of adult onset motor neuron disease in Scotland. Methodology, demography and clinical features of incident cases in 1989

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900618-9

Amyotrophic lateral sclerosis: current and future treatment strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900618-9

Amyotrophic lateral sclerosis: Part 1. Clinical features, pathology, and ethical issues in management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900618-9

Onset, natural history and outcome in idiopathic adult motor neuron disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900618-9

Survival prediction in amyotrophic lateral sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900618-9

Natural history of amyotrophic lateral sclerosis in a database population Validation of a scoring system and a model for survival prediction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900618-9

Riluzole preserves motor function in a transgenic model of familial amyotrophic lateral sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900618-9

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900618-9

What do we really know about amyotrophic lateral sclerosis?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900618-9

A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900618-9

2-Amino-6-trifluoromethoxy benzothiazole, a possible antagonist of excitatory amino acid neurotransmission--I. Anticonvulsant properties

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900618-9

Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900618-9

Markov models in medical decision making: a practical guide.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900618-9

An introduction to Markov modelling for economic evaluation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900618-9

Cost effectiveness of screening for and eradication of Helicobacter pylori in management of dyspeptic patients under 45 years of age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900618-9

A cost-utility analysis of laser-assisted angioplasty for peripheral arterial occlusions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900618-9

The Markov process in medical prognosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900618-9

Utility approach to measuring health-related quality of life

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900618-9

Application of multi-attribute utility theory to measure social preferences for health states

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900618-9

Patients' health-related quality of life and utilities associated with different stages of amyotrophic lateral sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900618-9

Visual analog scales, standard gambles, and relative risk aversion.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900618-9

Multiattribute utility function for a comprehensive health status classification system. Health Utilities Index Mark 2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900618-9

Incorporating utility-based quality-of-life assessment measures in clinical trials. Two examples

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900618-9

Measurement of health state utilities for economic appraisal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900618-9

Discounting and health benefits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900618-9

Cost effectiveness of riluzole in amyotrophic lateral sclerosis. Italian Cooperative Group for the Study of Meta-Analysis and the Osservatorio SIFO sui Farmaci.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900618-9

Cost-benefit analysis of riluzole for the treatment of amyotrophic lateral sclerosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900618-9

Modeling valuations for EuroQol health states

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900618-9

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0022-510X(01)00618-9

1 reference

22 September 2017

1 reference